Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Amneal Pharmaceuticals Stock Down 2.2%

AMRX traded down $0.39 on Thursday, hitting $17.27. The company had a trading volume of 2,244,046 shares, compared to its average volume of 2,168,140. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.15 and a 52-week high of $19.26. The stock has a fifty day simple moving average of $17.08 and a 200-day simple moving average of $14.54. The firm has a market capitalization of $5.51 billion, a P/E ratio of 35.24 and a beta of 1.27.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several large investors have recently modified their holdings of AMRX. Kemnay Advisory Services Inc. bought a new stake in Amneal Pharmaceuticals during the 4th quarter valued at about $26,000. Federated Hermes Inc. lifted its stake in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares in the last quarter. Comerica Bank grew its holdings in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares during the last quarter. Transamerica Financial Advisors LLC increased its position in shares of Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares in the last quarter. Finally, Focus Partners Wealth purchased a new position in Amneal Pharmaceuticals in the 3rd quarter worth approximately $42,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, July 29th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. The Goldman Sachs Group reiterated a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Finally, Barclays raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.